BC Innovations | Apr 16, 2015
Product R&D

Antagonizing psoriasis

Despite the heavy competition in psoriasis, AnaptysBio Inc. believes it can make a mark with a first-in-class antibody for a neglected, inherited form of pustular psoriasis caused by a loss-of-function mutation in the proinflammatory cytokine...
BC Innovations | May 15, 2014
Tools & Techniques

Blood test for asthma

Asthma is notoriously difficult to accurately diagnose because its symptoms can be transient and common tests are susceptible to user error. A University of Wisconsin-Madison team believes that it can improve the process by using...
BC Innovations | Apr 3, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Musculoskeletal disease Calcium release-activated calcium channel (CRAC); stromal interaction molecule 1 (STIM1); transmembrane protein 142A (ORAI1; TMEM142A; CRACM1) In vitro and genetic studies suggest...
BC Innovations | Oct 3, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Calcium release-activated calcium channel (CRAC) Cell culture studies suggest agonizing CRAC could be useful for treating AD. In human embryonic kidney (HEK)...
BC Week In Review | Sep 30, 2013
Clinical News

Rhizen preclinical data

In a guinea pig model of acute asthma, oral RP3128 reversed antigen-induced eosinophil infiltration vs. controls. RP3128 also significantly inhibited citric acid-induced cough reflex in sensitized guinea pigs vs. codeine (p<0.01). Data were presented at...
BC Innovations | Aug 15, 2013
Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Pancreatitis Calcium release-activated calcium channel (CRAC) Cell culture studies suggest antagonizing CRAC could help treat acute pancreatitis. In a pancreatic acinar cell model of...
BC Innovations | Aug 8, 2013
Targets & Mechanisms

CRACking pancreatitis

The handful of companies pursuing CRAC inhibitors for immunological disorders have a new indication to consider-acute pancreatitis. New findings from Cardiff University 1 show that the target plays a central role in the painful and...
BC Week In Review | Feb 21, 2011
Clinical News

CM2489: Phase I started

CalciMedica began a blinded, placebo-controlled, U.S. Phase I trial evaluating single ascending-doses of daily oral cm 2489 in 48 healthy volunteers. CalciMedica Inc. , La Jolla, Calif.   Product: cm 2489   Business: Autoimmune   Molecular...
BC Week In Review | Oct 20, 2008
Company News

CalciMedica, TorreyPines deal

CalciMedica exercised an option under a 2007 deal with TorreyPines to acquire IP related to the use of stromal interaction molecule-1 (STIM-1) and Ca release-activated Ca ( CRAC ) channel inhibitors to treat CNS disorders. TorreyPines received...
BioCentury | Dec 10, 2007
Emerging Company Profile

CalciMedica: CRACking toxicity

Calcineurin inhibitors are effective in preventing acute organ transplant rejection and treating autoimmune diseases, but their long-term use is associated with renal and hepatic toxicities. CalciMedica Inc. hopes to sidestep these toxicities by developing therapeutics...
Items per page:
1 - 10 of 13